CFTR and cystic fibrosis: Whether ETI has any beneficial effects on the liver of CF patients remain to be systematically studied, although some pre-ETI-era studies suggested that CFTR modulator drugs along (e.g., ivacaftor) or in combination [e.g., lumacaftor (VX-809)-ivacaftor (VX-770)] may provide benefits to the liver of CF patients (14–16).